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Available online xxxxBackground: The latent HIV-1 reservoir in treated patients primarily consists of resting memory CD4+ T cells.
Stimulating the T-cell receptor (TCR), which facilitates transition of resting into effector T cells, is themost effec-
tive strategy to purge these latently infected cells. Here we supply evidence that TCR-stimulated effector T cells
still frequently harbor latent HIV-1.
Methods: Primary HIV-1 infected cells were used in a latency assay with or without dendritic cells (DCs) and
reversion of HIV-1 latency was determined, in the presence or absence of speciﬁc pathway inhibitors.
Findings: Renewed TCR-stimulation or subsequent activation with latency reversing agents (LRAs) did not over-
come latency. However, interaction of infected effector cells with DCs triggered further activation of latent HIV-1.
When compared to TCR-stimulation only, CD4+ T cells from aviremic patients receiving TCR + DC-stimulation
reversed latency more frequently. Such a “one-two punch” strategy seems ideal for purging the reservoir. We
determined that DC contact activates the PI3K-Akt-mTOR pathway in CD4+ T cells.
Interpretation: This insight could facilitate the development of a novel class of potent LRAs that purge latent HIV
beyond levels reached by T-cell activation.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Activated T cells1. Introduction
Early on in HIV infection, cellular reservoirs containing latent HIV-1
are formed [1]. These cells contain a stably integrated and complete viral
genome, but do not express sufﬁcient amounts of viral proteins to drive
virus production and to be recognized by the immune system. Resting
memory CD4+ T cells are the main cell type harboring latent HIV-1 in
patients after prolonged therapy [2,3], but T cells with shorter half-
lives, such as effector T cells, can also harbor latent HIV-1 [4,5]. Latency
is established and maintained through multiple mechanisms that act at
transcriptional and post-transcriptional levels [6]. At the transcriptional
level, accessibility of the HIV-1 LTR promoter could be blocked inntfort).
en access article under the CC BY-NC
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dicine, https://doi.org/10.101repressive chromatin structures (which can be overcome with histone
deacetylase (HDAC) inhibitors) or by the sequestration of transcription
initiation factors such as NF-ĸB/NFAT/AP-1. Other blocks to HIV-1 tran-
scription include inefﬁcient elongation due to the lack of elongation fac-
tors such as P-TEFb or the presence of negative elongation factors
(NELFs). These elongation factors inﬂuence the RNA polymerase com-
plex and determine whether transcription is prematurely aborted
after synthesis of the trans-activation response (TAR) region or ex-
tended towards the formation of full-length HIV-1 RNA transcripts.
Yukl et al. recently described that HIV latency at the transcriptional
level occurs mainly due to inefﬁcient RNA elongation accompanied by
a lack of splicing and polyadenylation factors rather than the absence
of transcription initiation factors [7]. Inefﬁcient export of viral RNA
from the nucleus may also contribute to HIV-1 latency, either due to
low levels of Rev protein [8,9] or cellular co-factors like Matrin-3 or
PTB that assist in nuclear RNA export [10,11].-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Evidence before this study
Management of HIV has significantly improved over the past de-
cades, due to combinations of antiretroviral drugs preventing
viral replication. However, the virus cannot be eradicated because
of the so-called latent reservoir, primarily consisting of resting
memory CD4+ T cells. Several strategies to target this reservoir
have been tested, but none are satisfactory. Stimulating the T-
cell receptor (TCR), facilitating transition of resting into effector
T cells, is currently the most effective strategy to purge these la-
tently infected cells.
Added value of this study
Here we demonstrated that TCR-stimulated effector T cells can
still contain latent HIV-1. Renewed TCR-stimulation or activation
of such effector cells with latency reversing agents (LRAs) did
not overcome latency. We decided to concentrate on alternative
methods of activation next. We found that the interaction of in-
fected effector cells with dendritic cells (DCs) could further acti-
vate latent HIV-1. Using such a “one-two punch” strategy might
thus be ideal for purging the bodily latent reservoir. Indeed,
CD4+ T cells taken from aviremic patients, which received our
DC-stimulation on top of TCR-stimulation, more frequently re-
versed latency. Our experiments also showed that latency rever-
sal upon DC contact is due to the activation of the PI3K-Akt-
mTOR pathway in the target CD4+ T cells.
Implications of all the available evidence
These findings might aid the development of novel classes of po-
tent LRAs as drugs used to purge latent HIV beyond the current
levels reached by T-cell activation.
Fig. 1. Purging latent HIV-1 according to the “one-two punch” strategy. First, resting T cells
are activated by stimulating the T cell receptor. Activated effector T cells are subsequently
brought into contact with DCs to increase the purging efﬁciency of latent HIV-1.
Table 1
HIV-1 patient history.
Patient Age
(years)
Load
copies/ml
Current treatment CD4 Duration
UVL (years)
1 37 b40 TDF/FTC/EFV ND 4.2
2 81 b40 TDF/FTC/EFV 0.46 5.2
3 48 b40 DTG/3TC/ABC 0.38 2.4
4 48 b40 EVG/c/ TAF/FTC ND 1.2
5 54 b40 NVP/TDF/FTC ND 12.9
6 42 b40 EVG/c/ TAF/FTC 0.90 3.9
7 23 b40 EFV/3TC/ABC ND ≥4
8 50 b40 DTG/3TC/ABC 0.80 5.9
9 56 b40 LPV/r/TDF/FTC ND 12.7
10 52 b40 NVP/3TC/ABC 0.49 13,2
11 61 b40 RAL/DRV/r/TDF/FTC 0.38 8,6
12 50 b40 EVG/c/ TDF/FTC ND 12,9
13 55 b40 TDF/FTC/EFV 0.73 2,3
14 69 b40 NVP/TDF/FTC ND 11,5
15 24 b40 ATZ/r/3TC/ABC ND ≥1
16 41 b40 NVP/TDF/FTC 0.92 13,1
35 48 b40 s/r/TDF/FTC ND ≤14.2
36 62 b40 NVP/TDF/FTC ND ≤9.9
37 51 b40 DRV/r/RAL 520 ≥1.6
ND = Not determined.
TDF: tenofovir disoproxil fumarate; FTC: emtricitabine; EFV: efavirenz; DTG: dolutegravir;
3TC: lamivudine; ABC: abacavir; EVG/c: elvitegravir cobicistat; TAF: tenofovir
alafenamide; NVP: Nevirapine; LPV: lopinavir; r: ritonavir; RAL: raltegravir; DRV:
darunavir; ATZ: atazanavir ritonavir; s: Saquinavir.
2 T. van Montfort et al. / EBioMedicine xxx (2019) xxxOne of the proposed strategies to exhaust the reservoir is a “shock
and kill” treatment in which latency-reversing agents (LRAs) purge
HIV-1 from latency, while uninfected cells are protected against virus
infection with antiretroviral therapy. Virus-induced cell death or cyto-
toxic T-cell killing of virus-producing cells was proposed to eliminate
the reactivated cells. Stimulation of the T-cell receptor (TCR) to induce
the transition of resting into effector T cells is currently the most effec-
tive strategy to purge latent HIV. Ex vivo stimulation of the TCR with
PHA or CD3-CD28 antibodies can purge approximately 1 cell permillion
resting memory T cells (= 1 IUPM), as determined with the gold stan-
dard quantitative viral outgrowth assay (qVOA) [12]. Based on full-
genome sequencing, however, it has been estimated that the intact
HIV-1 reservoir size is around 30 cells per million resting T cells in
treated patients [12]. This implies that T-cell activation can only purge
a fraction of the HIV reservoir and that additional stimuli are required
to purge larger portions of latently infected cells. We previously devel-
oped an HIV-1 latency assay for activated effector T cells as opposed to
quiescent resting T cells [5]. Stimulation of these effector T cells with
DCs purged HIV-1 latency efﬁciently (~3-fold), whereas stimulation
with other LRAs had no impact on latency reversal. This in vitro HIV-1
latencymodel shows thatmanyHIV-1 infected T cells, although fully ac-
tivated, keep their latent state. This ﬁnding is corroborated with data
from an ex vivo study [13], using TCR stimulation of quiescent resting
patient T cells. Although the T cells were fully activated, a second
or third TCR-stimulation could further increase latency reversal 2–3
fold, implying that more is needed to purge activated latently infected
cells.Please cite this article as: T. van Montfort, R. van der Sluis, G. Darcis, et al
activating the PI3K-Akt-mTOR pat..., EBioMedicine, https://doi.org/10.101Herewewant to stress the difference between latentHIV-1 infection
reversal and cell activation and the fact that current strategies towards
human treatment rely on shifting resting T cells to activated pheno-
types. Cell activation however, is relatively inefﬁcient in also activating
latent HIV-1 expression. Our observations offer insights to guide new
approaches to increasing the efﬁciency of latent HIV-1 reversion. We
show that the PI3K-Akt-mTOR pathway has to be triggered to activate., Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation,
6/j.ebiom.2019.02.014
Fig. 2. Purging of latent HIV-1 in in vitro infected primary activated T cells with classical LRAs or DCs. A) Time-line of the HIV-1 latency assay. Pooled primary PBMCs from 10 healthy
individuals were activated with PHA for 2 days. CD8 T cells were removed and CD4-enriched PBMCs were expanded for three days before infecting them in vitro with HIV-1 for 4 h. Cell-
free virus was washed away and residual virus cell-fusion events and replication were blocked with the T1249 entry inhibitor. Proviral integration was allowed for 24 h prior to applying
various stimuli for another 48 h. B) Representative dot plot of CA-p24 and CD3 stained CD4-enriched T cells stimulated with or without DCs. C) Results are shown as percentage of virus
producing cells and fold activation. Shown data are the average of three independent experiments with standard error of the mean. D) Activation of latent HIV-1 with T cell receptor
agonist phytohaemagglutinin (PHA) and CD3/CD28 antibodies. E) Using different concentrations of the HDAC inhibitor romidepsin. F) Using different concentrations of the PKC activator
prostratin or TNFα (G). Representative data are shown with standard error of the mean of at least three independent experiments. Drug toxicity is indicated with .
3T. van Montfort et al. / EBioMedicine xxx (2019) xxxvirus production in PHA pre-activated T cells, which is achieved upon
DC contact. Importantly, we show that reversal of HIV-1 latency in T
cells isolated from treated aviremic patients (See Table 1), even when
activatedwith PHA, is further stimulated by DCs. DC coculture increases
the frequency ofHIV-1 release (all 9 patients) compared to PHAalone (4
out of 9). Using an adapted quantitative virological outgrowth assay
(qVOA), the golden standard to measure reversal of HIV-1 latency, we
found replicating virus in 8 out of 12 patients (starting at a baseline of
2 out of 12 patients upon PHA stimulation only) upon DC treatment.
Collectively, this “one-two punch” strategy (PHA + DCs) can purge
the reservoir more potently than PHA treatment alone (Fig. 1). These
ﬁndings could direct the development of novel LRA treatments that
also strongly stimulate the PI3K-Akt-mTOR pathway. The new insights
could also be used for the design of a new sensitive culture-based
assay to measure the intact HIV-1 reservoir.2. Material and methods
2.1. Reagents
The fusion inhibitor T1249 was obtained from Pepscan (Therapeu-
tics BV, Lelystad, The Netherlands) and used at a ﬁnal concentration ofPlease cite this article as: T. van Montfort, R. van der Sluis, G. Darcis, et al.
activating the PI3K-Akt-mTOR pat..., EBioMedicine, https://doi.org/10.101100 ng/ml. Antibodies against CD9, CD63, CD81, CD83, CD86, CD151,
CD45RO, CD45RA, were purchased from Biolegend (San Diego, CA,
USA). Other antibodies are directed against CA-p24 (clone KC-57RD1)
(Beckman Coulter, Brea, CA, USA) and CD3-APC (BD Pharmingen,
Breda, the Netherlands).2.2. Cells
Human peripheral blood mononuclear cells (PBMCs) were isolated
from buffy coats (Central Laboratory Blood Bank, Amsterdam,
The Netherlands) by use of a Ficoll gradient and frozen in multiple
vials. When required, PBMCs were thawed, activated with
phytohaemagglutinin (PHA, Remel, 2 μg/ml) and cultured in RPMI me-
dium supplementedwith 10% FCS and recombinant human IL-2 (rhIL-2,
Novartis, 100 U/ml). On day 2 of culture, CD8+ T lymphocytes were de-
pleted using CD8 immunomagnetic beads (Dynal, Invitrogen, Carlsbad,
CA, USA) and the CD4+-enriched T lymphocytes were cultured for 3
more days before use in the in vitro latency assay.
Monocytes were isolated from PBMCs with CD14 magnetic beads
from Miltenyi Biotec (GmbH, Bergisch Gladbach, Germany) according
to the manufacturer's protocol. Puriﬁed monocytes were cultured in
RPMI 1640 medium containing 10% FCS and differentiated into, Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation,
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4; Biosource, Nivelles, Belgium) and 500 U/ml granulocyte macrophage
colony-stimulating factor (GM-CSF; Schering-Plough, Brussels,
Belgium) on day 0 and 2, and used on day 6 [14].
HEK 293 T cells were grown as a monolayer in Dulbecco's minimal
essential medium (Gibco, BRL, Gaithersburg, MD) supplemented with
10% (v/v) fetal calf serum (FCS), 40U/ml penicillin, 40 μg/ml streptomy-
cin at 37 °C and 5% CO2.
SupT1 CCR5 expressing T cells, a kind gift of prof. J. Hoxie [15] were
cultured in RPMI 1640 medium containing 10% FCS.
2.3. Virus
Plasmid DNA encoding the CXCR4-using HIV-1 LAI primary isolate
was transiently transfected in HEK293T cells with the lipofectamin
2000 reagent according to manufacturer's protocol (Fisher Scientiﬁc,
Landsmeer, NL). Virus supernatant was harvested 2 days after transfec-
tion, passed through a 0.2 μm ﬁlter and stored in aliquots at−80 °C. The
concentration of the virus stocks was determined by CA-p24 ELISA.
2.4. In vitro HIV-1 latency assay
HIV-1 infected cells were used in the latency assay as described pre-
viously [16, 19, 20]. In short, PHA-activated CD4+ T lymphocytes (1.5
× 106 or 2.0 × 106 cells) were infected with HIV-1 for 4 h (20 ng CA-
p24). To establish infection over a 4 h window, excess virus was diluted
with three washes and cells were incubated with 100 ng/ml T1249
fusion inhibitor to prevent late fusion events and new rounds of virus
replication. Cells were incubated for 24 h to allow HIV-1 proviralFig. 3. Reversion of latency depends on speciﬁc tetraspanin enriched microdomains
formed between DCs and T cells. A) Fold activation from latency of infected primary T
cells cultured with or without DCs in the presence of 20 μg/ml CD9, CD63, CD81 and
CD151 antibodies targeting speciﬁc tetraspanin enriched microdomains (TEMs).
B) Schematic overview, adapted from Hemler et al. [22], regarding the role of the
tetraspanins targeted in activating the RAS signaling cascade. Phosphatidylinositol 4-
kinase is recruited to the membrane in CD9, CD63, CD81 TEMs and phosphoinositides,
such as phosphatidylinositol-4,5- bisphosphate (PI(4,5)P2) are produced. This causes
activation of Shc, resulting in the activation of the RAS signaling pathway. CD151
negatively inﬂuences the RAS activation pathway [22]. Representative data are plotted
as the average fold activation with standard error of the mean of at least three
independent experiments.
Please cite this article as: T. van Montfort, R. van der Sluis, G. Darcis, et al
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(ratio DC:T 1:3), with or without 20 μg/ml CD9/CD63/CD81/CD151 an-
tibody, or in the presence or absence of drugs for 48 h in the continued
presence of T1249. Single cells were analysed for the presence of the
CD3 T cell receptor and expression of intracellular CA-p24 by ﬂow cy-
tometry [5,16]. The percentage of CA-p24 positive CD3-positive cells
in the treated culture was divided by the percentage of CA-p24 cells in
the mock treated culture and reported as fold activation (a measure of
HIV-1 latency reversion).
2.5. Intracellular CA-p24 analysis
Cells wereﬁxed in 4% formaldehyde at room temperature for 20min
and subsequently washedwith 2% FACS buffer (PBS supplementedwith
2% FCS). The cells were permeabilisedwith BD Perm/Wash™ buffer (BD
Pharmingen) and antibody stainingwas performed in BD Perm/Wash™
at room temperature for 1 h. HIV-1 was intracellularly stained with an
CA-p24 antibody and T lymphocytes were discriminated from DCs
using the T cell receptor CD3 antibody. Unbound antibodywas removed
and the cells were analysed on a BD Canto II ﬂow cytometer with BD
FACSDiva Software v6.1.2 (BD biosciences, San Jose, CA) in FACS buffer.
The T lymphocyte population was deﬁned based on forward/sideward
scatter andCD3 expression. Virus production on the gated T lymphocyte
population was determined bymeasuring the intracellular viral CA-p24
protein level. Dendritic cells and T cell doublets were removed from the
analyses by gating.
2.6. Human phospho kinase array
PHA-activated CD4+ T lymphocytes were infected according to the
in vitro HIV-1 latency assay protocol. Infected PBMCs (15 × 106) were
incubated with 7 × 106 DCs or without DCs for 2.5 h. To disrupt the
DC-T cell interaction, which was observed after 1 h incubation, cell cul-
tures were resuspended and washed twice in cold PBS supplemented
with 2 mM EDTA and 0.5% FCS. CD4+ T lymphocytes were isolated at
4 °C using the human CD4+ T lymphocytes isolation kit from Miltenyi
Biotec according to the manufacturer's protocol. Approximately 10
× 106 CD4+ T lymphocytes were obtained after the isolation protocol.
Cells were pelleted and treated according to the manufacturer's proto-
col from the human phospho-kinase antibody array kit (R&D systems).
2.7. Ethical approval
Informed written consent was obtained from all participants of this
study, and the study was approved by the Medical Ethical Committee
of the Academic Medical Center, Amsterdam. All procedures followed
were in accordance with the ethical standards of the responsible com-
mittee on human experimentation (institutional and national) and
with the Helsinki Declaration of 1975, as revised in 2000.
2.8. Quantiﬁcation of HIV-1 release into culture supernatant
Patient-derived CD4+T cellswere isolated using thehumanCD4+T-
lymphocyte isolation kit (Miltenyi Biotec) according to themanufactur-
er's protocol. Between 1.4 and 2.0 × 106 cells were used per condition
and treated with 2 μg/ml PHA, heterologous monocyte-derived DCs in
a 1:3 ratio (DC:T), PHA combined with DCs (1:3 ratio) or left untreated
for 72 h in RPMI1640medium containing rhIL-2 and 80 ng/ml saquina-
vir. Cell-free supernatant was collected by centrifugation for 5 min at
500 rcf. Extracellular HIV-1 RNA was isolated from 300 μl of the super-
natant using the Boom isolation method [17] with the addition of 2 μg
of carrier RNA (poly A RNA, Qiagen, Venlo, The Netherlands) and proc-
essed for reverse transcription and ﬁrst PCR using QIAGEN® OneStep
RT-PCR kit (Qiagen, Venlo, The Netherlands) according to themanufac-
turer's instructions. The primers used were TAR-F (5′-GGGTCTCTCTG
GTTAGACCAG-3′) and HIV-FOR [18]. The PCR settings were as follows:., Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation,
6/j.ebiom.2019.02.014
Fig. 4. Purging of latent HIV-1mediated by DCs depends on PI3K, not MEK-ERK signaling. A) Schematic overview of inhibitors targeting speciﬁc signaling pathways. B) Infected primary T
cells were cultured with or without DCs in the presence of the MEK inhibitor U0126, or C) the PI3K inhibitor pictilisib, or D) the PTEN inhibitor SF1670. Drug toxicity is indicated with .
5T. van Montfort et al. / EBioMedicine xxx (2019) xxx94 °C for 3min, followed by 15 cycles of 94 °C for 30 s, 55 °C for 30 s, and
72 °C for 1 min, followed by 72 °C for 10 min. Two μl of the ﬁrst PCR
product were subsequently used as a template in the second, semi-
nested, real-time, PCR ampliﬁcation, performed using the primers and
a TaqMan probe described by Malnati et al. [18].
2.9. qVOA with 1) PHA, 2) DC one-two punch
Isolated CD4+ T cells from aviremic patients were activated with 2
μg/ml PHA for 72 h in RPMI1640 medium containing rhIL-2 and
100 ng/ml entry inhibitor T1249. Cells were washed three times and
cultured in 96-well plate with a cell density of 2.0 × 105 CD4 T cells/
well with or without 8.3 × 104 DCs (1:3 DC:T cell ratio) in fresh
RPMI1640 containing rhIL-2. HIV-1 susceptible SupT1 CCR5 cells (5.0
× 104) were added to the microcultures to disseminate and sustain
HIV-1 replication [19]. After 7, 14 and 21 days of culturing half of the
culture was used to determine HIV-1 CA-p24 by ELISA [5] and fresh
RPMI 1640 media containing 5.0 × 104 SupT1 CCR5 cells was added to
sustain T cell growth and virus replication. The number of infectious
units per million (IUPM) cells was determined on the number of HIV-
1 CA-p24 positive microcultures on day 21 for each condition per mil-
lion patient-derived CD4 T cells.
2.10. Statistical analysis
Signiﬁcance of differences between groups or pairs was determined
by one-way ANOVA and Student's t-tests. For patient-derived samples,
Fisher's exact tests were used to compare the detectability of HIV-1
extracellular RNA between different conditions. Signiﬁcance levels: *:
p b .05; **: p b .01; ***: p b .001. All tests were two-sided and were per-
formed using GraphPad Prism, version 7.Please cite this article as: T. van Montfort, R. van der Sluis, G. Darcis, et al.
activating the PI3K-Akt-mTOR pat..., EBioMedicine, https://doi.org/10.1013. Results
3.1. Dendritic cells purge residual latent HIV-1 from PHA-activated T cells
To investigate the effectiveness of DCs or LRAs in reversing latency in
effector T cells,we designed an innovative primary T-cellmodel. Resting
T cells from healthy donors were activated with PHA for 2 days. CD8+ T
cells were removed and CD4+ T cells were cultured for three days be-
fore infection for 4 hwith HIV-1. New rounds of infection and virus rep-
lication were then blocked by addition of the T1249 entry inhibitor.
Cells weremaintained in culture for 24 h to allow completion of reverse
transcription andDNA integrationwas allowed to proceed for 24h. Sub-
sequently, the infected CD4+ T cells were co-cultured for 48 h with or
without DCs and in the presence or absence of LRAs (Fig. 2A). As
shown before, the percentage of virus-producing T cells increased
from 7.5% to 28.2% by DC co-culturing (Fig. 2B). Reversion of latency,
expressed as “fold activation” by calculating the percentages of CA-
p24 positive DC-treated T cells divided by control untreated T cells
from three independent infections, was ~3.5-fold (Fig. 2C). Importantly,
this means that for each virus-producing effector T cell, 2 to 3 additional
HIV-infected cells could be purged from latency by DCs. Thus, a bigger
part of the reservoir could be purged using DCs as an extra stimulation.
The observed rate of reversion of HIV-1 latency by DCs is not due to in-
creased viral transmission or integration as extending the period before
addition of DCs or use of the integrase inhibitor raltegravir did not
change the fold activation. Moreover, the infected activated effector T
cells showed heightened expression levels of CD25, CD69, CD45RO
and CCR7 and the additional DC stimulation did not change expression
levels [5].
Successive stimulation of the T-cell receptor (TCR) has been shown
to increasingly revert the level/efﬁciency of HIV latency in activated T, Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation,
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6 T. van Montfort et al. / EBioMedicine xxx (2019) xxxcells [13]. The heterologous DCs used in this latency assay might also
have non-speciﬁcally stimulated the TCR. Re-stimulating the TCR
again with phytohaemaglutinin (PHA) or CD3/CD28 antibodies, how-
ever, did not purge latency, demonstrating that DC-purging is not trig-
gered via the TCR (Fig. 2D). Other LRAs such as the HDAC inhibitor
romidepsin (Fig. 2E), the PKC activator prostratin (Fig. 2F), and the in-
ﬂammatory cytokine TNFα (Fig. 2G) were also unable to revert addi-
tional latent HIV-1, illustrating that reversion of HIV-1 triggered by
DCs is different from the LRAs tested and does not depend on T cell re-
ceptor activation.3.2. Tetraspanins are involved in DC-triggered HIV-1 activation in PHA-
activated T cells
DCs interact with T cells via immunological synapses where antigen
is presented for TCR recognition. Tetraspanins CD9, CD63, CD81, and
CD151 play an important role in this process by stabilizing recruited
protein complexes in tetraspanin-enriched microdomains (TEMs)
[20,21]. To investigate whether the tetraspanins are involved in DC-
mediated HIV-1 latency reversal in T cells, tetraspanin-speciﬁc antibod-
ies (Ab) were added. Blocking of CD9 abrogated HIV-1 latency reversal
in effector T cells by DCs, beyond mock-incubated T cell levels. CD9
also showed a negative effect on activation in T cells in the absence of
DCs (Fig. 3A), implying that latency is induced. CD63 also blocked DC-
mediated reversal of latency and modestly induced latency in non-DC
treated T cells. A reduction of ~38% in DC-mediated purging was ob-
served when a CD81 Ab was used while the CD151 Ab had no effectFig. 5. Effects of targeting the PI3K-Akt-mTOR signaling transduction cascade on latency rever
B) Fold activation from latency of infected primary T cells cultured with or without DCs in the
AZD8055, D) Akt inhibitor MK2206, E) mTORC1 inhibitor temsirolimus, or F) inhibitor of nucle
the average fold activation with standard error of the mean at the different indicated concentra
Please cite this article as: T. van Montfort, R. van der Sluis, G. Darcis, et al
activating the PI3K-Akt-mTOR pat..., EBioMedicine, https://doi.org/10.101onDC-purging (Fig. 3A). These data suggest that the RAS signaling path-
way is targeted by DCs, because the three responsive tetraspanins (CD9,
CD63 and CD81) activate this pathway, whereas the non-responsive
CD151 tetraspanin inhibits it (Fig. 3B, model adapted from Hemler
et al. [22].3.3. DC-mediated HIV-1 latency reversal depends on the PI3K-Akt-mTOR
pathway
Active GTP-bound RAS can activate the extracellular signal-
regulated kinase (Raf-MEK/ERK), phosphoinositide kinase 3 (PI3K-
Akt-mTOR) and the phospholipase C (PLC)/PKC pathway (Fig. 4A). As
shown above, stimulation of the TCR or the PKC pathway with
prostratin did not purge latent HIV-1 in effector T cells, illustrating
that the PLC-PKC pathway is not involved in DC-purging (Fig. 2D and
F). Inhibiting the Raf-MEK/ERK pathwaywith increasing concentrations
of theMEK1/2 inhibitor U0126 (up to 100 nM) also did not block HIV-1
purging (Fig. 4B) and cell death was observed at 300 nM. In contrast, in-
hibition of the PI3K route with 100 nM pictilisib (GDC-0941) potently
inhibited DC purging (Fig. 4C).
To conﬁrm the involvement of the PI3K pathway, we indirectly acti-
vated this pathway by inhibiting PTEN with SF1670 (Fig. 4A and D). In
accordance with the suggested role of the PI3K-Akt-mTOR pathway
in latency reversal, inhibition of PTEN in the T-cell culture reversed
HIV-1 latency by 1.7-fold. In contrast, inhibition of PTEN increased the
DC-purging activity only minimally (and only at high concentrations
of SF1670), suggesting that the PI3K-Akt pathway was already active.sal. A) Schematic overview of inhibitors targeting the PI3K-Akt-mTOR signaling pathway.
presence of the PI3K/mTORC2/mTORC1 inhibitor GSK2126548, C) PI3K/mTORC1 inhibitor
ar factor kappa-B kinase (IKK) antagonist bardoxolone. Representative data are plotted as
tions of inhibitor from three independent cultures. Drug toxicity is indicated with .
., Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation,
6/j.ebiom.2019.02.014
Fig. 6. Transcription factors binding NF-ĸB and SP1 target sites in the LTR promoter do not seem to be involved in DC-dependent latency reversal. A) Fold activation of infected primary T
cells culturedwith or without DCs in the presence of JSH-23, inhibiting nuclear translocation of the transcription factor NF-ĸB, B) in the presence of SP600125 inhibiting dimerization of c-
Jun transcription factors binding SP1motifs, or C) the inhibitor T5224 inhibiting c-Fos-c-Jun dimerization. Representative data are plotted as the average fold activationwith standard error
of themean at the different indicated concentrations of inhibitor from three independent cultures. Of note, blocking activation of transcription factors beyond the indicated concentrations
of JSH-23 and SP600125 was toxic for T cells regardless of whether they were co-cultured with DCs (results not shown).
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To conﬁrm involvement of the PI3K-Akt-mTOR pathway, we tested
additional inhibitors that block speciﬁc steps of this pathway (Fig. 5A).
The inhibitor GSK2126548 that blocks the activation of PI3K, mTORC1
and mTORC2, the mTOR-inhibitor AZD8055 that blocks activation of
mTORC1 and mTORC2, and the Akt-inhibitor MK2206 all inhibited DC-
mediated HIV-purging in a dose-dependent manner (Fig. 5B-D). These
inhibitors had no signiﬁcant effect on HIV-1 production in T-cell only
cultures, but a negative purging trend seemed to occur. The results
again illustrate that an active mTOR pathway in activated T cells is in-
volved in the induction of virus production [23]. We used the inhibitor
temsirolimus to speciﬁcally inhibit mTORC1, which inhibited DC-
mediated reversion of latent HIV-1 by 70% at concentrations as low as
10 nM, without any cell toxicity (Fig. 5E). Inhibiting the IκB kinase
(IκK) complex, another signaling branch downstream of Akt with
bardoxolone also blocked HIV-1 reactivation, but only at high concen-
trations above 100 nM (Fig. 5F). In summary, although the PLC, PKC,
MEK/ERK and PI3K/Akt pathways are activated in PHA-activated T
cells, a further stimulation of the PI3K/Akt pathway by DC contact
purged latent HIV-1 beyond the level of TCR activation.
3.5. DC contact does not increase availability of nuclear NF-ĸB or cJun/cFos
(hetero/homo) dimers
The IκK pathway is involved in activation of the transcription factor
NF-ĸB. To explorewhether the purging effectmediated byDCs is depen-
dent on increased transcription initiation, we blocked nuclearPlease cite this article as: T. van Montfort, R. van der Sluis, G. Darcis, et al.
activating the PI3K-Akt-mTOR pat..., EBioMedicine, https://doi.org/10.101translocation of NF-ĸB with JSH-23 [24], which did not inhibit DC-
mediated reversal of latency up to 3 μM(Fig. 6A). Higher concentrations
of JSH-23 partially inhibited the DC purging effect, but these high con-
centrations also induced latency in the absence of DCs. This result illus-
trates that latency can be induced by blocking nuclear translocation of
the NF-ĸB, but the purging ability observed with DCs is not dependent
on increased production or translocation of NF-ĸB. Blocking c-Jun
(Fig. 6B) or c-Fos (Fig. 6C), transcription factors that bind to AP-1 and
SP1 sites in the HIV-1 LTR promoter, also did not affect DC-mediated
purging. Thus, the availability of transcription factors that are important
for HIV-1 gene expression in activated effector T cells is sufﬁcient and is
not changed upon DC addition.
3.6. DCs trigger (de)phosphorylation of proteins downstream of the Akt sig-
naling pathway
To explore which pathways become activated by DCs in effector T
cells,we also studied the phosphorylation status of 43 proteins fromdif-
ferent signaling cascades. Seven proteins that belong to the Akt signal-
ing pathway became phosphorylated upon 2.5 h DC contact
(p38alpha, JNK1/2/3, GSK-3AB, p53, CREB, c-Jun and WNK-1) (Fig. 7A
and C). Surprisingly, two other proteins that are also associated with
Akt signaling, p27 and p70SK6, became dephosphorylated. It could be
that these kinases were dephosphorylated to prevent over-activation
of the mTOR pathway via negative feedback loops. Apart from the
over-all activation of the Akt pathway, we also observed STAT5/6 pro-
teins being less frequently phosphorylated after DC contact. We then
analysed the phosphorylation status after an extended (21h) DC, Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation,
6/j.ebiom.2019.02.014
Fig. 7. Characterization of phosphorylated protein kinases in infected primary CD4+ T cells upon coculturing with DCs. PHA-activated CD4-enriched T cells are infected according to the
in vitro latency assay and cocultured with DCs, for A) 2 h or B) 21 h. DC treated and untreated CD4+ T cells are isolated with the CD4+ isolation kit (Miltenyi), pelleted and lysed at 4
degrees. Of the 43 kinases analysed using the human-phospho kinase array from R&D systems, only differentially phosphorylated kinases with N25% up- or downregulation (indicated
with red and orange dotted line) compared to untreated cells are shown. C) Activating and inhibitory signaling cascades with corresponding phosphorylation status of kinases for the
Akt, MEK-ERK signaling pathway are shown schematically [56,57]. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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pathway still showed an increased phosphorylation status (Fig. 7B).
Thus, part of the PI3K-Akt-mTOR pathway in T cells remains active
upon prolonged DC contact. Overall, these results provide evidence
that DCs activate the PI3K-Akt-mTOR pathway in T cells, thus purging
latent HIV-1 proviruses.
3.7. DCs purge latent HIV-1 in TCR activated CD4 cells from aviremic
patients
Since DCs activate the PI3K-Akt-mTOR pathway and purge latent
HIV-1 in activated T cells, we examined whether they can also purge la-
tent HIV-1 beyond PHA-mediated activation in CD4+ T cells from
aviremic HIV-infected patients. CD4+ T cells were isolated from 9
aviremic ART-treated patients and stimulated with PHA or mock-
treated in the absence or presence of heterologous DCs for 72 h. Purging
of HIV-1 latencywas assessed by the detection of extracellular HIV-1 vi-
rion RNA released into the cell culture supernatant. In mock-stimulated
CD4+ T cells, HIV-1 RNA could be detected for 4 out of 9 patients
(Fig. 8A). Treatment with PHA, however, also did not increase the de-
tectability of HIV-1 RNA when compared to mock-stimulated CD4+ T
cells and DC contact even slightly decreased the HIV+ scores, possibly
due to consumption of free virus in the supernatant [25,26]. Impor-
tantly, a combined PHA + DC treatment made HIV-1 RNA detectable
for 9 out of 9 patients, implying that non-responding patients cellsPlease cite this article as: T. van Montfort, R. van der Sluis, G. Darcis, et al
activating the PI3K-Akt-mTOR pat..., EBioMedicine, https://doi.org/10.101(with PHA only), responded with virus production upon the DC stimu-
lus (Fig. 8B). The analyses however showed that the mean amount of
RNA produced upon combined treatment was not increased compared
to a single PHA treatment, which again could be due to the capture of
free virus by DCs.
Next, we tested reversion of latency from single cells with the quan-
titative virological outgrowth assay (qVOA) on CD4+ T cells from 10
aviremic patients. Due to a limited number of patient cells, obtained
from 15 ml of blood, we performed the qVOA with a cell density of
200.000 T cells per culture. With this number of T cells, if all cultures
are positive, a maximal IUPM of 5 can be reached. An increased number
of IUPM cells was observed for the PHA+ DC treatment compared to a
single PHA shock. For 4 patients replicating virus only grewoutwith the
PHA + DC treatment. For two patients (10 and 12) an increased IUPM
level was observed with the double treatment and no virus outgrowth
occurred upon PHA or PHA + DC treatment for 3 patients (Fig. 8C and
D). Therefore, we conclude that DCs can purge HIV-1 latency beyond
levels achieved by PHA activation.
4. Discussion
The latent HIV-1 reservoir in patients under suppressive ART con-
sists predominantly of long-lived resting memory CD4+ T cells [27]. A
major proportion of the reservoir contains replication-incompetent
proviral DNA that lacks gene fragments, is hypermutated, or is., Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation,
6/j.ebiom.2019.02.014
Fig. 8. Purging of latentHIV-1 frompatient-derived resting primary T cellswithDCs. Isolated CD4+ cells (1.4–2.0 ×106) fromaviremicHIV-1 patientswere culturedwith orwithout PHA in
presence or absence of DCs (ratio 1:3 DC:T cell) for 72 h. A) Copy numbers of HIV-1 extracellular RNA released into cell culture supernatant, as determined by RT-qPCR. Median values are
represented by horizontal lines. The dotted line represents the detection limit of the assay. The undetectable values were plotted as 50% of the detection limit. B) Percentage plot of
detectable versus undetectable HIV-1 RNA. C) Outgrowth of replication competent HIV-1 measured at day 21 from 10 aviremic patient-derived CD4+ T cells activated with PHA or
PHA + DCs. Reversal of latency is depicted as infectious units per million cells (IUPM) based on the number of CA-p24 negative and positive microcultures. Median values are
represented by horizontal lines. D) Percentage plot of detectable versus undetectable replication competent HIV-1 after differential stimulation for these patient samples.
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proximately 30 resting T cells per million still contain infectious
replication-competent HIV-1 genomes [12]. TCR activation that con-
verts resting T cells into effector T cells can only purge HIV-1 in approx-
imately 1 resting T cell per million [12,30]. Even though a full T-cell
activation status is reached, sequential stimulation with a second TCR-
based stimulus can increase the purging efﬁciency 2–3 fold [13], sug-
gesting that latency persisted in most activated T cells. To study if
more complete purging is feasible, we developed an HIV-1 latency
model with (TCR pre-stimulated) primary effector T cells [5]. We pro-
vide evidence implicating DC contact in efﬁciently purging latent HIV
in these T cells, something not achieved by a second round of T-cell ac-
tivation or treatment with other LRAs (Fig. 2). Thus, the one-two punch
consisting of TCR activation and subsequent stimulus with DCs can
reach a signiﬁcantly larger portion of the reservoir than other purging
methods.
Using CD4+ T cells isolated from ART-treated aviremic patients, we
conﬁrmed results obtained with our in vitro latency model by showing
that ex vivo TCR-stimulation combined with DC contact induced the re-
lease of HIV-1 RNA into the supernatant in a signiﬁcantly larger propor-
tion of patients compared with TCR stimulation alone, which is
indicative for purging of latent HIV-1 [31]. Although RNA could be de-
tected for all patients with the double treatment, the levels of RNA re-
leased were not increased. This could be caused by efﬁcient capture
and degradation of free HIV-1 by DCs [25,26], which will strongly limit
the amount of HIV-1 RNA to be detected in supernatant. In agreement
with this hypothesis, treatment of patient cells with DCs alone without
PHA activation also decreased the amount of RNA released in superna-
tant compared to untreated cells. To understand why DCs increase thePlease cite this article as: T. van Montfort, R. van der Sluis, G. Darcis, et al.
activating the PI3K-Akt-mTOR pat..., EBioMedicine, https://doi.org/10.101purging efﬁciency we dissected the molecular mechanisms induced in
T cells pretreated with PHA. Our data illustrate that formation of
tetraspanin-enriched microdomains (TEMs) between DCs and T
cells is important for the purging ability of DCs (Fig. 3A) [20,32–34].
These TEMs recruit PI4K to the membrane to locally produce
phosphoinositols, such as phosphatidylinositol-4,5 bisphosphate
(PtdIns(4,5)P2), which activate RAS via Shc proteins [22,35]. GTP-
bound RAS can activate the MEK-ERK, PLC-PKC and the PI3K-Akt-
mTOR pathway. TheMEK-ERK and PLC-PKC pathways are strongly acti-
vated upon TCR stimulation, achieved with the ﬁrst PHA stimulus,
which promotes HIV-1 transcription by increasing the levels of acti-
vated transcription factors such as NF-ĸB [36,37]. Restimulating the
TCR with CD3/CD28 Abs or PHA again did not increase HIV-1 latency
purging, indicating that both these pathways are still fully activated.
Stimulationwith DCs, however, purged latency efﬁciently. Thiswas pre-
dominantly caused by activation of the PI3K-Akt-mTOR pathway. Acti-
vation of this pathway is associated with improved RNA elongation,
ribosomal activity, protein synthesis and cell survival [38]. Thus, activa-
tion of the PI3K-Akt-mTOR probably overcomes post-transcriptional
blocks to form infectious viral particles.Whether activation of this path-
way is strictly regulated via RAS activation or via other DC-T cell medi-
ated interactions needs to be explored in future research.
We hypothesize that phosphoinositols, especially the availability of
PtdIns(4,5)P2, determines HIV-1 latency at various levels (Fig. 9). First,
transcription factors such as NF-ĸB or c-Jun/c-Fos are required for HIV-
1 transcription initiation [30,31,38]. These factors are upregulated via
TCR stimulation, where PtdIns(4,5)P2 is converted by PLC into IP3 and
DIAG in the MEK-ERK and PLC-PKC pathway [39]. Second, PI3K-Akt-
mTOR pathway activation is required to allow transcriptional, Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation,
6/j.ebiom.2019.02.014
Fig. 9. Reversion of HIV-1 latency regulated by DCs. Binding of DCs to T cells is facilitated by tetraspanin membrane molecules that recruit interacting DC-T cell proteins in tetraspanin
enriched microdomains (TEMs) to induce multiple signaling events. Recruitment of PI4K to CD9/CD63/CD81 TEM leads to local production of PI(4,5)P2. DC-dependent activation of
PI3K further phosphorylates PI(4,5)P2 into PI(3,4,5)P3, which activates PDK1 to induce recruitment of Akt to the membrane. Akt docking to PI(3,4,5)P3 triggers activation followed by
activation of downstream signaling cascades such as mTORC1 or IKK that promote transcription and protein synthesis reactivating latent HIV-1 in active proliferating cells. The
signaling cascade that is responsible for DC-mediated reversion of latent HIV-1 independent of T cell receptor activation is indicated with bold arrows.
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PtdIns(4,5)P2 production in TEMs via PI4K activation and subsequent
phosphorylation into PtdIns(3,4,5)P3 by PI3K. Since the PI3K-Akt-
mTOR and PLC-PKC pathway either phosphorylate or dephoshorylate
PtdIns(4,5)P2, strong activation of either one of these pathways will di-
rectly inhibit the activation of the other pathway. Thus, a ﬁne balance
between these pathways should be pursued to purge latent HIV-1, or
both pathways should be activated sequentially as achieved for instance
with our “one-two punch” strategy, in which, after transcription initia-
tion, RNA elongation and protein translation should follow.
In this light it is not surprising that TCR stimulation, which can trig-
ger sub-optimally the PLC-PKC and PI3K-Akt-mTOR pathway, has some
HIV-1 purging ability, leading to outgrowth of infectious particles. Solely
activating the transcription initiation route using a PKC agonist, how-
ever, does not [30]. Interestingly, a recent study discovered the impor-
tance of the mTOR pathway in purging latent HIV-1 in resting cells
[23]. Speciﬁcally blocking the mTOR pathway after TCR stimulation ne-
gated reversal of latency in patient cells, illustrating that TCR-
stimulation can sub-optimally activate this pathway. Our results extend
those data by showing that activation of the PI3K-Akt-mTOR pathway
by DCs, is stronger than stimulating the TCR in isolation, leading to in-
creased purging efﬁciency.
Targeting multiple intermediates in the PI3K-Akt-mTOR pathway,
e.g. using small molecule inhibitors, we dissected their contributions
in reverting latency. For instance using GSK2126458, we found that it
inhibited DC-speciﬁc activation of the PI3K-AKt-mTOR pathway better
than the mTORC1 inhibitor temsirolimus. This is in agreement with aPlease cite this article as: T. van Montfort, R. van der Sluis, G. Darcis, et al
activating the PI3K-Akt-mTOR pat..., EBioMedicine, https://doi.org/10.101study from Martin et al., who reported that the mTORC1 inhibitor
rapamycin [40,41] did not block purging of latent HIV-1, but could re-
duce the toxic side effect of CD3/CD28 T cell activationwithout affecting
CTL-mediated killing [42]. The use of small molecule inhibitors can have
off-targets effects as well as general toxicities, which can distort results.
In as far as possible our controls excluded these as a source of error. Our
ﬁndings regarding the activation of the PI3K-Akt-mTOR pathway upon
DC contact were futher corroborated by phosphate modiﬁcation read-
outs. This again argues against aspeciﬁc effects of the small molecule
inhibitors.
DC contact may inﬂuence HIV-1 reactivation in T cells by additional
means. Ren et al. showed thatmature DCs are capable of releasing TNFα
upon contact with infected Jurkat T cells, leading to reversion of latency
in this cell line [43].
Since DCs strongly revert HIV-1 latency, it would be an option to use
DCs as a natural cell source to revert HIV-1 latency in HIV-infected pa-
tients. We previously observed that primary DCs homing to different
lymphoidorganshave substantiallydifferent latency-purgingcapacities.
Monocyte-derivedDCs culturedunder conditions towards a gutDCphe-
notype efﬁciently purged latent HIV-1, whereas no, or only modest, re-
versal of latency was achieved with DCs representing the subtype
homing to the genital tract. Myeloid DCs that have been matured with
different toll-like receptor agonists, representing lymph node derived
DCs, efﬁciently purge HIV-1 from latency [16]. The fact that monocyte-
derived DCs can purge HIV-1 from patient-derived latently infected
cells suggests that DCsmight control the size of the viral reservoir in pa-
tients in particular tissues. This could happen especiallywhen T cells are., Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation,
6/j.ebiom.2019.02.014
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when T cells are activated to ﬁght the HIV-1 infection [5]. DC-mediated
HIV-1 reversion however, is not to be expected in peripheral blood
[16], as the frequency of myeloid DCs is ~7000 per million CD4 T cells
in healthy donors, with even lower numbers in HIV-1 infected individ-
uals (~2300 per million) [44]. But, DC:T contact might be more efﬁcient
in tissues,which could result in the observed low levels of ongoing virus
production, even in the presence of therapy [45,46].
Interestingly, Gramatica and colleagues already raised the possibility
that latency reversal might bemore effective in lymphoid tissueswhere
contact of T cells with DCs is more prominent than in blood [47]. The
lack of efﬁcacy of clinical trials using LRAs aimed at decreasing the
HIV-1 reservoir size might therefore be caused by the fact that the res-
ervoir was analysed only in the peripheral blood and not in tissues,
where preferential DC-mediated purging could occur [48–52]. One ap-
proach to use DCs to increase the LRA purging efﬁciency in patients
might be the combination of an LRA with speciﬁc TLR agonists that
will direct DCs to tissues, where latent reservoirs are maintained. The
use of DCs as a natural mechanism to revert HIV-1 latency has caveats
and limitations, due to difﬁculties inherent in speciﬁc targeting of this
interaction. However, if feasible this approach will have limited side ef-
fects [53] compared to using T cell receptor agonists [54].
Our results could have important implications. Firstly, the potent
capacity of DCs to reactivate HIV-1 proviruses which were not purged
despite PHA stimulation could be used to design a more sensitive
culture-based assay to measure the replication-competent reservoir,
for instance by adapting the promising TZM-bl based assay [55]. Sec-
ondly, the role of DCs in HIV-1 persistence highlights the need to look
at tissue reservoirs when possible, since cell-to-cell contact appears to
be a major factor controlling HIV-1 latency. Finally, our results further
support the importance of the PI3K-Akt-mTOR pathway in HIV-1 la-
tency. These novel insights could be used to develop more efﬁcient
LRA strategies in the quest to get rid of the latent HIV-1 reservoir.
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